| Literature DB >> 32545258 |
Matteo Balzarro1, Emanuele Rubilotta1, Nicolò Trabacchin1, Antonio Soldano1, Clara Cerrato1, Filippo Migliorini1, Vito Mancini2, Antonio Luigi Pastore3, Antonio Carbone3, Luigi Cormio2, Giuseppe Carrieri2, Alessandro Antonelli1.
Abstract
We evaluate the early and late safety and efficacy of silver nanoparticle (AgNPs) in wound healing after circumcision. This multicenter prospective comparative non-randomized observational study compares wound dressing with AgNPs (group A) vs. gentamicin cream (group B). Follow-up included objective evaluation at 10 and 30 days by the Southampton Scoring System (SSS) and Stony Brook Scar Evaluation Scale (SBSES). We enrolled 392 males: 194 in group A, and 198 in group B. At 10 days follow-up, in group A, the SSS scale was grade 1 in 49.5% and grade 2 in the remaining; meanwhile, in group B, grade 1 was in 58%, grade 2 in 34.3%, and grade 4 in 7.6%. At 30 days follow-up, grade 1 healing was 97.4% and 98.4% in group A and B, respectively. At 10 days follow-up, the mean SBSES score was 3.58 and 3.69 in group A and B, respectively; while at 30 days follow-up, 4.81 and 4.76 in group A and B, respectively. Only in group B did 7.6% of males have antibiotic therapy due to pus discharge. No patients needed surgical wound revision. AgNPs led to a late but safer healing, they were non-inferior to the antibiotic cream wound dressing efficacy, and they avoided pus discharge and the need for oral antibiotics due to their polymer material.Entities:
Keywords: AgNPs; circumcision; silver nanoparticles; wound dressing
Year: 2020 PMID: 32545258 PMCID: PMC7356923 DOI: 10.3390/jcm9061822
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Demographics characteristics of group A and B.
| Group A, | Group B, | |
|---|---|---|
| Population | 194 | 198 |
| Mean age | 36.2 | 37.4 |
| Ethnicity | Caucasian 194 (100%) | Caucasian 198 (100%) |
| Indication for surgery | ||
| Idiopathic phimosis | 188 (96.9%) | 189 (95.4%) |
| Lichen Sclerosus phimosis | 8 (3.1%) | 9 (4.5%) |
| Cancer phimosis | 0 (0%) | 0 (0%) |
| Co-morbidities | ||
| No co-morbidities | 161 (83%) | 165 (83.3%) |
| Controlled diabetes | 11 (5.7%) | 12 (6.1%) |
| Hypertension | 12 (6.2%) | 13 (6.6%) |
| Vasculopathy | 6 (3.1%) | 5 (2.5%) |
| Metabolic disorders | 16 (8.2%) | 14 (7.1%) |
| Therapies | ||
| Oral diabetic therapy/insulin | 11 (5.7%) | 12 (6.1%) |
| Antihypertensive therapy | 10 (5.6%) | 10 (5.1%) |
| Antiplatelet/anticoagulant | 13 (6.7%) | 15 (7.6%) |
| Metabolic therapies | 11 (5.7%) | 12 (6.1%) |
| Alpha adrenergic therapy | 9 (4.6%) | 7 (3.5%) |
| Previous urological surgeries | 7 (3.6%) | 8 (4%) |
Wound healing in the two groups analyzed by the Southampton Scoring System and Stony Brook Scar Evaluation Scale at 10- and 30-day follow-ups.
| 10 Days f-Up | 30 Days f-Up | |||||
|---|---|---|---|---|---|---|
| Group A | Group B | P | Group A | Group B | P | |
| Grade 0 | - | - | 97.4% | 98.4% | 0.45 | |
| Grade I | 49.5% | 58.0% | 0.88 | 2.6% | 1.6% | 0.45 |
| Grade II | 50.5% | 34.3% | 0.001 | - | - | |
| Grade III | - | - | - | - | ||
| Grade IV | - | 7.6% | - | - | - | - |
| Grade V | - | - | - | |||
* Fisher exact test.
Circumcision cosmetic healing evaluated by the Stony Brook Scar Evaluation Scale.
| 10 Days f-Up | 30 Days f-Up | |||||
|---|---|---|---|---|---|---|
| Stony Brook Scar |
|
| P |
|
| P |
| Mean score | 3.58 | 3.69 | 0.064 * | 4.81 | 4.76 | 1 * |
| SD score | ± 1.1 | ± 1.2 | ± 0.4 | ± 0.3 | ||
* T student test.